Skip to main content
Oncopeptides logo

Oncopeptides — Investor Relations & Filings

Ticker · ONCO ISIN · SE0009414576 LEI · 549300J9WWQ5CBYQ1M77 ST Manufacturing
Open in API
Filings indexed 483 across all filing types
Latest filing 2018-12-05 Remuneration Information
Country SE Sweden
Listing ST ONCO

About Oncopeptides

https://www.oncopeptides.com/en

Oncopeptides is a biotechnology company focused on the research, development, and commercialization of targeted therapies for difficult-to-treat cancers. The company concentrates on hematological diseases, with a primary focus on multiple myeloma. Its commercialized product is Pepaxti (melflufen), a peptide-drug conjugate for adult patients with relapsed or refractory multiple myeloma. Founded in 2000 based on research from leading cancer institutions, Oncopeptides leverages its proprietary technology platforms to advance a pipeline of innovative drug candidates. The company's research also includes the development of Natural Killer (NK) cell engagers to address unmet medical needs in oncology.

Recent filings

Filing Released Lang Actions
Bulletin from the Extraordinary General Meeting in Oncopeptides AB (PUBL)
Remuneration Information Classification · 1% confidence The document is explicitly titled "BULLETIN FROM THE EXTRAORDINARY GENERAL MEETING IN ONCOPEPTIDES AB (PUBL)" and details the resolutions passed at this meeting, including the election of a new board member and the approval of remuneration and an incentive program for that member. This content directly relates to the governance and proceedings of a shareholder meeting, specifically reporting the outcomes. This aligns perfectly with the definition of AGM Information (AGM-R), which covers presentations and materials shared during the Annual General Meeting (or in this case, an Extraordinary General Meeting, which falls under the same category of meeting-related outcomes). Although it reports voting results (DVA), the primary context is the overall meeting bulletin reporting multiple decisions, making AGM-R the most appropriate fit for general meeting outcomes.
2018-12-05 English
Interim data from the ongoing HORIZON trial with melflufen presented in an oral presentation at the 60th American Society of Hematology Meeting
Earnings Release Classification · 1% confidence The document is explicitly titled as a "Press release" dated December 3, 2018, announcing "Interim data from the ongoing HORIZON trial with melflufen presented in an oral presentation at the 60th American Society of Hematology Meeting." It details clinical trial results (ORR, PFS, safety profile) and provides context on the drug and ongoing studies. This format—a formal announcement of periodic clinical data or trial updates released via press release—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is not a comprehensive quarterly/interim financial report (IR) or the full Annual Report (10-K), and it is a specific announcement of results rather than just a notice of publication (RPA), the best fit among the provided options for a press release detailing periodic operational/clinical results is 'Earnings Release' (ER), as clinical trial updates often accompany or substitute for traditional earnings highlights in biotech/pharma. Given the specific nature of clinical data presentation, it is a form of periodic operational update. FY 2018
2018-12-03 English
Interimsdata från den pågående HORIZON-studien med melflufen presenteras i en muntlig presentation vid det 60:e Amerikanska Hematologimötet (ASH)
Earnings Release Classification · 1% confidence The document is a press release from Oncopeptides AB, dated December 3, 2018, announcing the presentation of interim data from the HORIZON study (testing melflufen) at the 60th American Society of Hematology (ASH) meeting. It details clinical results (ORR, PFS, safety profile) and provides context on the drug's mechanism and ongoing trials (OCEAN, ANCHOR, BRIDGE). This format—a detailed announcement of clinical trial results and scientific updates, often timed around major medical conferences—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses heavily on presenting new scientific/clinical data rather than just summarizing quarterly financials (ER) or being a formal regulatory filing (RNS), and it is not a full report (10-K, IR), it best fits the 'Earnings Release' category as it serves as the primary public disclosure of performance/progress data, even if not strictly quarterly financial earnings. Given the context of presenting clinical trial results, ER is the closest fit among the options for a major operational update announcement. FY 2018
2018-12-03 Swedish
Oncopeptides presents first interim data from the ongoing combination trial ANCHOR with melflufen at the 60th American Society of Hematology Meeting
Earnings Release Classification · 1% confidence The document is a press release announcing the presentation of interim clinical trial data (ANCHOR study results for melflufen) at a medical conference (ASH Meeting). It contains key financial/clinical results (ORR, response rates), CEO comments, and details about ongoing clinical trials. This format—a formal announcement of results outside of a mandated periodic report (like 10-K or IR)—is characteristic of an Earnings Release (ER) or a general press release detailing operational/clinical progress. Since it focuses heavily on presenting interim clinical data and operational updates rather than just the final quarterly/annual financial figures, and it is structured as a news announcement, 'Earnings Release' (ER) is the most appropriate classification among the options, as it often encompasses significant operational milestones like major data presentations. It is not a full financial report (10-K or IR), nor is it a transcript (CT) or a formal investor presentation (IP), but rather the announcement of the data itself. FY 2018
2018-12-01 English
Oncopeptides presenterar de första interimsresultaten från den pågående kombinationsstudien ANCHOR med melflufen vid det amerikanska hematologimötet
Earnings Release Classification · 1% confidence The document is a press release from Oncopeptides AB dated December 1, 2018, announcing the presentation of 'the first interim results' from the ANCHOR combination study of melflufen at the 60th ASH meeting. It details clinical data (ORR, toxicity, patient demographics) and includes commentary from the CEO and background on the drug and ongoing studies. This content structure—presenting key financial/clinical results for a specific period or event (a conference presentation)—is characteristic of an Earnings Release (ER) or a general announcement of clinical data. Since it is a detailed release of interim clinical results, it aligns best with the 'Earnings Release' (ER) category, which covers initial announcements of periodical financial/clinical results, even though this is clinical data rather than strictly quarterly financials. It is not a full Annual Report (10-K), a formal Audit Report (AR), or a simple Report Publication Announcement (RPA) as it contains substantial analysis and data, not just a notice that a report is available. Given the context of presenting study results, ER is the most appropriate fit among the provided options. FY 2018
2018-12-01 Swedish
Antal aktier och röster i Oncopeptides
Share Issue/Capital Change Classification · 1% confidence The document is a press release dated November 30, 2018, announcing a change in the total number of outstanding shares and votes due to the exercise of stock options ('utnyttjande av teckningsoptioner'). This directly relates to a change in the company's capital structure (share count and share capital increase). Based on the definitions, this aligns best with 'Share Issue/Capital Change' (SHA), which covers announcements regarding new share issues or capital changes. It is not a general financing update (CAP) but a specific notification about the resulting share count.
2018-11-30 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.